The HSE has asked the National Centre for Pharmacoeconomics (NCPE) to evaluate the manufacturers (Roche Products Ltd) economic dossier on the cost effectiveness of pertuzumab. The NCPE uses a decision framework to systematically assess whether a technology is cost effective. This includes clinical effectiveness and health related quality of life benefits which the new treatment may provide and ...